Canaccord Genuity Reiterates a 'Buy' on Zalicus (ZLCS); New Exalgo dosing; Synavive Data Soon
Tweet Send to a FriendGet Alerts ZLCS Hot Sheet
Price: $0.56 --0%
Rating Summary:
4 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Rating Summary:
4 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Trade ZLCS Now!
Canaccord Genuity reiterates a 'Buy' on Zalicus (NASDAQ: ZLCS) price target of $3.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on Synavive’s potential in rheumatoid arthritis (RA) and emerging pain platform. Synavive is ZLCS’ Ph2 drug for RA, with major market potential in various conditions treated with low dose chronic steroids. ZLCS also has a promising ion channel modulator platform for chronic pain, including Ph2a-ready Z160, a novel Ca2+ channel blocker."
"FDA approves 32mg Exalgo; we expect higher dose will improve practicality of use in chronic pain patients. The average Exalgo dose required by patients in Ph3 for adequate pain control was ~37mg/day. Thus opioid Rx pill restrictions on the previously approved 8, 12 and 16mg doses were a barrier to use. We think the increased dose will have a meaningful benefit to Exalgo sales, allowing more patients to be able to reach therapeutic effect with the allowed number of pills."
For an analyst ratings summary and ratings history on Zalicus click here. For more ratings news on Zalicus click here.
Shares of Zalicus closed at $1.38 yesterday, with a 52 week range of $0.72-$1.70.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Ritu Baral, said, "Reiterate rating and price target on Synavive’s potential in rheumatoid arthritis (RA) and emerging pain platform. Synavive is ZLCS’ Ph2 drug for RA, with major market potential in various conditions treated with low dose chronic steroids. ZLCS also has a promising ion channel modulator platform for chronic pain, including Ph2a-ready Z160, a novel Ca2+ channel blocker."
"FDA approves 32mg Exalgo; we expect higher dose will improve practicality of use in chronic pain patients. The average Exalgo dose required by patients in Ph3 for adequate pain control was ~37mg/day. Thus opioid Rx pill restrictions on the previously approved 8, 12 and 16mg doses were a barrier to use. We think the increased dose will have a meaningful benefit to Exalgo sales, allowing more patients to be able to reach therapeutic effect with the allowed number of pills."
For an analyst ratings summary and ratings history on Zalicus click here. For more ratings news on Zalicus click here.
Shares of Zalicus closed at $1.38 yesterday, with a 52 week range of $0.72-$1.70.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- AcelRx (ACRX) Target Lifted at Jefferies
- Rackspace (RAX) Sentiment Could Turn on News of New Customer
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
